Who is this relevant for?
- Manufacturers evaluating UK market entry
- Distributors monitoring sourcing opportunities
- Hospitals managing supply risk for HAE treatments
Chiesi Group has agreed to acquire KalVista Pharmaceuticals for $1.9bn, adding the first oral on-demand therapy for hereditary angioedema (HAE) to its rare immunology portfolio. The deal includes sebetralstat (marketed as EKTERLY), a plasma kallikrein inhibitor that treats HAE attacks in adults and adolescents.
Sebetralstat reached $49m in sales after its US launch in July 2025. It is already approved in the US, EU, UK, Japan, and other regions. Filings are underway to expand use to children aged 2–11, and additional market approvals are in progress.
For pharma operators, this acquisition signals a shift in HAE management from injectables to an oral option. Supply chains for oral tablets differ from injectables—cold chain requirements are eliminated, and patient adherence may improve. Chiesi gains a differentiated product and expands its US commercial footprint, supporting its 2030 revenue target of €6bn.
Transaction is expected to close in Q3 2026, subject to regulatory approvals and tender conditions. Chiesi plans to leverage KalVista's capabilities and integrate the therapy into its Global Rare Diseases unit.
Distributors and hospitals should monitor supply plans for sebetralstat, especially as pediatric approval broadens the addressable patient population. Manufacturers evaluating UK or EU market entry may note Chiesi's strengthened rare disease pipeline and the growing preference for oral on-demand therapies.